A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2018
At a glance
- Drugs TSR 033 (Primary) ; TSR 042 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms CITRINO
- Sponsors TESARO
- 03 May 2018 According to a TESARO media release, the Company expects to initiate assessment in Q2 2018 and report Phase 1 monotherapy dose-escalation data for TSR-033 in 2H 2018.
- 27 Feb 2018 According to TESARO media release, the Company expects to report monotherapy dose-escalation data in 2H 2018.
- 10 Aug 2017 According to an AnaptysBio media release, TESARO received clearance of an Investigational New Drug application (IND) for TSR-033.